CURRICULUM VITAE
PERSONAL INFORMATION
Name: Nadeem R. Khan, M.D.
Address: 4729 N. Habana Ave Tampa, FL 33614
4 Columbia Drive, Suite 820 Tampa, Florida 33606
Research Address: 4200 North Armenia Avenue Suite 3 and Suite 5 Tampa, Florida 33607
Date of Birth: October 3, 1968
Place of Birth: Chicago, Illinois
Citizenship: USA
Marital Status: Married, 3 children Wife: Mehr
Foreign Language: Hindi, Urdu, and Spanish
Medical License: Illinois 2000 Florida, 2003
EDUCATION
College and Medical School:
Karachi University Baqai Medical College 51 Deh Tor, Gadap Road Post Office Box 2407 Karachi, Pakistan
Degree: Bachelor of Medicine and Bachelor of Surgery
Date: December 1990-February 1995
POSTGRADUATE TRAINING
Residency: The New York Hospital and Medical Center-Queens 56-45 Main Street Flushing, NY 11355 Type: Transitional
Date: July 1996-June 1997
Residency: Ravenswood Hospital and Medical Center 4550 North Winchester Avenue Chicago, IL 60640
Type: Internal Medicine
Date: July 1997-June 2000
Residency: Ravenswood Hospital and Medical Center 4550 North Winchester Avenue Chicago, IL 60640
Type: Chief Resident
Date: July 2000-June 2001
Fellowship: University of South Florida College of Medicine 12900 Bruce B. Downs Blvd., MCD Box 19 Tampa, FL 33612-4799
Program: Infectious Diseases
Date: July 2001- June 2003
LICENSURE AND CERTIFICATES
Diplomate, Educational Commission of Foreign Medical Graduates, 3/1995-6/1996.
Diplomate, American Board of Internal Medicine, 2000.
Diplomate Infectious Diseases, American Board of Internal Medicine, 2004.
HONORS
Community Service Award, Ravenswood Hospital Medical Center, June 1999.
Honors Top 1% Medical School Class for Biochemistry, Pharmacology, Community Medicine, Surgery and Ophthalmology.
EXPERIENCE
Associate, International Travelers Clinic of Tampa Bay, July 2003 – present.
Associate, Infectious Disease Associates of Tampa Bay, July 2003 – present.
ACADEMIC APPOINTMENTS
Attending Physician, Private Medicine Teaching Service, University of South Florida College of Medicine, Tampa, Florida, 2003
HOSPITAL APPOINTMENTS
Vice Chief of Medicine, Memorial Hospital of Tampa, Tampa, Florida, 2006-Current.
HOSPITAL COMMITTEES
Associate Director, St. Joseph’s Hospital Tampa Care Clinic, 4200 North Armenia Avenue, Tampa, Florida 33607, 2003.
Associate Director, St. Anthony’s Pinellas Care Clinic, St. Petersburg, Florida, 2003.
ASSOCIATED ACTIVITIES
PROFESSIONAL ORGANIZATIONS
Member, American Medical Association, 2002-Current
Member, Infectious Disease Society of America, 2002-Current
Member, American College of Physicians, 2002-Current
PUBLICATIONS Khan NR: Unusual Case Studies of Bartonellisis (Printing in Progress) Greene J, Khan NR: Infections in Cancer, Chapter (To Be Determined, In Progress)
RESEARCH EXPERIENCE
“HIV/AIDS Clinical Trials“, Hillsborough county Health Department, Tampa, Florida, 2002-2003
PUBLICATIONS
Khan NR: Unusual Case Studies of Bartonellisis (Printing in Progress)
Greene J, Khan NR: Infections in Cancer, Chapter (To Be Determined, In Progress)
CO-INVESTIGATOR
Protocol No. EPZ108859. Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonovir + the Abacavir/Lamivudine Fixed Dose Combination Tablet (ABC/#TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/#TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naïve HIV-1 Infected HLA-B*5701 Negative Subjects. GlaxoSmithKline.
Protocol No. GS-US-183-0130. A Phase 3, Open Label, Multicenter Study of the Safety of Ritonovir-Boosted GS-9137 (GS-9137/r) Administered in Combination with other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects. Gilead Sciences.
Protocol No. GRZ107460. A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy versus Placebo Over 10 days in HIV-1 Infected Adults. GlaxoSmithKline.
Protocol No. M06-802. A Phase 3, Randomized, Open-label Study of Lopinavir/ritonovir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-experienced, HIV- 1 Infected Subjects. Abbott Laboratories.
Protocol No. TMC125-214. Early Access of TMC125 in Combination with other antiretrovirals in Treatment Experienced HIV-1 Infected Subjects with Limited Treatment Options. Tibotec Pharmaceuticals Limited.
Protocol No. GS-US-183-0105. A Phase II, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy. Gilead Sciences, Inc.
Protocol No. GS-US-0115. A Phase 4, Prospective, Open-Label, Multi-Center Study of the Safety, Efficacy, and Adherence in HIV Infected, Antiretroviral Naïve Patients Treated with a Simple Once-Daily Regimen. Gilead Sciences, Inc.
Protocol No: A4001028. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. Pfizer, Inc.
Protocol No. TMC125-C206. A Phase III Randomized, Double-Blinded, Placebo- Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC 125 as Part of an ART Including TMC 114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects with Limited to No Treatment Options. Tibotec Pharmaceuticals Limited.
Protocol No. TMC125-C217. An Open-Label Trial with TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects who Participated in a DUET Trial (TMC125-C206 and TMC 125-C216). Tibotec Pharmaceuticals Limited.
Protocol No. TMC114-C214. A Randomized, Controlled, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment- Experienced HIV-1 Infected subjects. Tibotec Pharmaceuticals Limited.
Protocol No. EPZ104057. A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naïve HIV-1 Infected Subjects. GlaxoSmithKline.
Protocol No. TNX-355.03. A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 with Optimized Background Therapy in Treatment-Experienced Subjects Infected with HIV-1. Tanox, Inc.
Protocol No.GS-01-934. A phase III, Randomized, Open-Label, Multicenter Study of the Treatment of Antiretroviral-naïve, HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination with Efavirenz Versus Combivir (Lamivudine/Zidovudine) and Efavirenz. Gilead Sciences, Inc.
Protocol 1182.12, RESIST 1: Randomized, Open-Label, Comparative Safety And Efficacy Study Of Tipranavir Boosted With Low-Dose Ritonavir (TPV/RTV) Versus Genotypically- Defined Protease Inhibitor/Ritonavir (PI/RTV) In Multiple Antiretroviral Drug Experienced Patients. Boehringer Ingelheim.
Protocol No. CCR102881. A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multi-Center, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination with COMBIVIR (lamivudine and zidovudine) upon Selected Immunological and Virological Markers of HIV- 1 Infection in Antiretroviral Therapy Naïve Subjects. GlaxoSmithKline.
Protocol No. ML18018. A 12-Week, Prospective, Open-label, Multi-Center, Cohort Study to Assess HIV-Patient Quality of Life and Tolerability after Administration of Enfuvertide- Containing HAART (QUALITE). Roche Laboratories, Inc.
Protocol No. 1182.58. An Open-Label Safety Study to Evaluate the Safety of Tipranavir plus Ritonavir When Used in Combination with Other Agents for the Treatment of Patients with HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options. Boehringer Ingelheim.
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100 mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naïve HIV-1 Infected Adults over 48 Weeks. GlaxoSmithKline.
Protocol 1182.17, A Long-Term, Open-Label Rollover Trial Assessing The Safety And Tolerability Of Combination Tipranavir And Ritonavir In Use In HIV-1 Infected Subjects. Boehringer Ingelheim.